Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression

Por Verstovsek, Srdan
Publicado em 2013

Preclinical and Clinical Experience with Dasatinib in Philadelphia Chromosome-Negative Leukemias and Myeloid Disorders

Por Verstovsek, Srdan
Publicado no Leuk Res (2008)

Ruxolitinib for myelofibrosis: from “palliation” to prolongation of survival

Por Verstovsek, Srdan
Publicado no Oncology (Williston Park) (2013)

Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis

Por Verstovsek, Srdan
Publicado no Leuk Lymphoma (2013)

Therapeutic Potential of JAK2 Inhibitors for the Management of Myelofibrosis

Por Verstovsek, Srdan
Publicado no Clin Cancer Res (2010)

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis

Por Verstovsek, Srdan
Publicado no Postgrad Med (2013)

Therapeutic potential of JAK2 inhibitors

Por Verstovsek, Srdan
Publicado no Hematology Am Soc Hematol Educ Program (2009)

Myeloproliferative neoplasms biology and therapy /

Por Verstovsek, Srdan, Tefferi, Ayalew
Publicado em c201

Eosinophilia in hematologic disorders

Por Falchi, Lorenzo, Verstovsek, Srdan
Publicado no Immunol Allergy Clin North Am (2015)

Paroxysmal Nocturnal Hemoglobinuria (PNH) is not a Cause for Anemia in Patients with Myelofibrosis

Por Nazha, Aziz, Verstovsek, Srdan
Publicado no Leuk Lymphoma (2014)

A Comprehensive Review of Pacritinib in Myelofibrosis

Por Verstovsek, Srdan, Komrokji, Rami S.
Publicado no Future Oncol (2015)

Novel and emerging therapies for the treatment of polycythemia vera

Por Verstovsek, Srdan, Komrokji, Rami S
Publicado no Expert Rev Hematol (2014)

Prognosis of primary myelofibrosis in the genomic era

Por Bose, Prithviraj, Verstovsek, Srdan
Publicado no Clin Lymphoma Myeloma Leuk (2016)

Emerging drugs for myelofibrosis

Por Atallah, Ehab, Verstovsek, Srdan
Publicado no Expert Opin Emerg Drugs (2012)

Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms

Por Atallah, Ehab, Verstovsek, Srdan
Publicado no Expert Rev Anticancer Ther (2009)

Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms

Por Bose, Prithviraj, Verstovsek, Srdan
Publicado no Expert Opin Investig Drugs (2016)

JAK2 Inhibitors: What’s the true therapeutic potential?

Por Santos, Fabio P S, Verstovsek, Srdan
Publicado no Blood Rev (2010)

Therapy with JAK2 inhibitors for Myeloproliferative Neoplasms

Por Santos, Fabio P. S., Verstovsek, Srdan
Publicado no Hematol Oncol Clin North Am (2012)

JAK2 inhibitors: are they the solution?

Por Santos, Fabio P. S., Verstovsek, Srdan
Publicado no Clin Lymphoma Myeloma Leuk (2011)

Efficacy of Ruxolitinib for Myelofibrosis

Por Santos, Fabio P S, Verstovsek, Srdan
Publicado no Expert Opin Pharmacother (2014)